Related Experiment Video

Updated: Aug 21, 2026

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

Beta-amyloid-derived pentapeptide RIIGLa inhibits Abeta(1-42) aggregation and toxicity

Lívia Fülöp1, Márta Zarándi, Zsolt Datki

  • 1Department of Medical Chemistry, University of Szeged, Dóm tér 8, Szeged, Hungary. fulopl@index.hu <fulopl@index.hu>

Biochemical and Biophysical Research Communications
|October 7, 2004
PubMed

Insights

A new pentapeptide, RIIGL(a), prevents beta-amyloid (Abeta(1-42)) aggregation and toxicity. This peptide shows potential for developing new neuroprotective drugs against Abeta-related neurodegenerative diseases.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Peptide Chemistry

Background:

  • Beta-amyloid (Abeta) peptides are implicated in neurodegenerative diseases.
  • Pr-IIGL(a), an Abeta(31-34) derivative, shows paradoxical effects: toxicity in neuroblastoma cells but protection against Abeta(1-42) in glial cells.

Purpose of the Study:

  • To synthesize and investigate a new pentapeptide, RIIGL(a), to understand the differential effects of Abeta derivatives.
  • To evaluate the aggregation properties and biological activities of Pr-IIGL(a) and RIIGL(a).

Main Methods:

  • Synthesis of Pr-IIGL(a) and RIIGL(a).
  • Transmission electron microscopy (TEM) for fibril formation.
  • Congo red binding assays.
  • Cytotoxicity assays in neuroblastoma cultures.
  • Co-incubation studies with Abeta(1-42).

Main Results:

  • Pr-IIGL(a) forms fibrillar aggregates and is cytotoxic to neuroblastoma cells.
  • RIIGL(a) does not form fibrils and lacks inherent toxicity.
  • RIIGL(a) inhibits Abeta(1-42) fibril formation and reduces its cytotoxicity.

Conclusions:

  • RIIGL(a) effectively inhibits both the aggregation and toxic effects of Abeta(1-42).
  • RIIGL(a) serves as a promising lead compound for designing novel neuroprotective peptidomimetics against amyloid-related pathologies.

More Related Videos

Preparation of Oligomeric &beta;-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices04:41

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Published on: July 14, 2010

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...